InMode Ltd. (INMD)
Market Cap | 956.95M |
Revenue (ttm) | 392.41M |
Net Income (ttm) | 175.78M |
Shares Out | 67.87M |
EPS (ttm) | 2.29 |
PE Ratio | 6.15 |
Forward PE | 8.23 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,971,487 |
Open | 14.23 |
Previous Close | 14.42 |
Day's Range | 13.80 - 14.28 |
52-Week Range | 13.68 - 19.85 |
Beta | 2.02 |
Analysts | Hold |
Price Target | 17.56 (+24.54%) |
Earnings Date | Apr 28, 2025 |
About INMD
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women’s health conditions and procedu... [Read more]
Financial Performance
In 2024, InMode's revenue was $394.82 million, a decrease of -19.76% compared to the previous year's $492.05 million. Earnings were $181.28 million, a decrease of -8.41%.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for INMD stock is "Hold." The 12-month stock price forecast is $17.56, which is an increase of 24.54% from the latest price.
News

InMode Q1 Earnings: Short-Term Catalysts Have Vanished (Rating Downgrade)
InMode's Q1 2025 results disappointed, with revenue and EPS missing estimates, leading to a 12% stock drop and another potential guidance cut. Despite solid fundamentals and attractive valuation, weak...

InMode: Equity Value Hinges On Cash, Not Future Prospects (Rating Downgrade)
InMode's Q1 2025 earnings reveal a 3% YoY revenue decline and margin compression, signaling continued macroeconomic pressures and underutilization of installed platforms. Management's revised 2025 gui...

Eyes On Park Introduces Revolutionary Envision by InMode System for Advanced Dry Eye Treatment in New York City
New York, New York--(Newsfile Corp. - April 28, 2025) - Eyes On Park, a leading optometry practice in Gramercy Park, announces the introduction of the cutting-edge Envision by InMode system for compr...

InMode Ltd. (INMD) Q1 2025 Earnings Call Transcript
InMode Ltd. (NASDAQ:INMD) Q1 2025 Earnings Conference Call April 28, 2025 8:30 AM ET Company Participants Miri Segal - CEO, MS-IR Moshe Mizrahy - CEO Yair Malca - CFO Conference Call Participants Mat...

InMode Reports First Quarter 2025 Financial Results; Quarterly Revenue of $77.9 Million Represents 3% Year-Over-Year Decrease
In April 2025, Completed Recent Share Repurchase Program of 6.95 Million Shares YOKNEAM, Israel, April 28, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of inn...

InMode: Strategic Capital Allocation Unlocks Shareholder Value (Rating Upgrade)
I upgrade InMode to Buy due to improved capital allocation, including significant share buybacks and potential for record dividends. Despite a 20% revenue decline in 2024, InMode remains a strong cash...

InMode to Present at the 24th Annual Needham Virtual Healthcare Conference
YOKNEAM, Israel , March 26, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chief Executive Officer, ...

InMode Responds to Doma Perpetual's Letters
Clarifies Capital Allocation Strategy and Commitment to Shareholder Returns Refutes Misconceptions on Staffing and Production Asserts No Justification for Additional Legal Action YOKNEAM, Israel , Mar...

InMode to Present at Upcoming Investor Conferences
YOKNEAM, Israel , March 3, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor co...

InMode: Plastic Surgery Boom, Cash Flow, And Cheap
InMode is significantly undervalued, with strong cash flow, international expansion, and investments in research and marketing driving future revenue and free cash flow growth. The company benefits fr...

InMode Ltd. (INMD) Q4 2024 Earnings Call Transcript
InMode Ltd. (NASDAQ:INMD) Q4 2024 Results Conference Call February 4, 2025 8:30 AM ET Company Participants Miri Segal - CEO, MS-IR Moshe Mizrahy - Chief Executive Officer Michael Kreindel - Chief Tec...

InMode Reports Fourth Quarter and Full Year 2024 Financial Results; Board of Directors Has Approved a New Share Repurchase Program
Quarterly GAAP revenues of $ 97.9 million and full year revenue of $394.8 million Returned $285.4 million of capital to shareholders in full year 2024 Together with new 10% program, represents repu...

InMode to Participate in the BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference
YOKNEAM, Israel , Feb. 3, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will h...

InMode: A Clear Bargain With Unique Risks
InMode Ltd. boasts superior fundamentals, yet trades at undervalued market multiples due to its unique risk profile. The company is a leader in the global aesthetics market with proprietary RF-based t...

InMode to Report Fourth Quarter & Full Year 2024 and Hold Conference Call on February 4, 2025, Earlier than Originally Announced
Conference call rescheduled to Tuesday, February 4, 2025, at 8:30 a.m. Eastern Standard Time YOKNEAM, Israel, Jan. 16, 2025 /PRNewswire/ -- InMode Ltd.

DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Immediately Execute Tender Offer followed by Share Buyback
Believes the Board Must Immediately Execute a Tender Offer for 30% of the Company Lays Out Action Plan to Restore Investor Confidence, Including an additional 10% Share Buyback in 2025 Announces Inten...

InMode: Clearly, I Was Too Optimistic (Rating Downgrade)
I'm downgrading InMode from a 'Strong Buy' to a 'Buy' due to consistent guidance cuts and short-term demand issues. Despite recent performance issues and high interest rates, INMD still holds a strong...

InMode to Report Fourth Quarter & Full Year 2024 Financial Results and Hold Conference Call on February 6, 2025, Expects Q4 Revenue Between $97.0M-$97.5M
Conference call to be held on Thursday, February 6, 2025, at 8:30 a.m. Eastern Standard Time YOKNEAM, Israel, Jan. 8, 2025 /PRNewswire/ -- InMode Ltd.

InMode: Product Origination And Undervaluation Make The Stock A Buy
InMode Ltd. demonstrates impressive net income growth from non-invasive surgical products, with new platforms Define and Envision expected to drive future business growth. The company's innovative tec...

InMode: $25/Share Is Closer Than You Think
Elevated interest rates continue to hurt InMode's revenue, especially as lease package interest rates haven't fallen yet. Still, future rate cuts could release pent-up demand. InMode continues to buy ...

InMode: A Deep Dive After Q3 Earnings
InMode's products are part of the medical aesthetics industry that is expected to grow at an 11% CAGR over the next five years. Despite a punishing macro environment of late that has seen its share pr...

InMode Ltd. (INMD) Q3 2024 Earnings Call Transcript
InMode Ltd. (NASDAQ:INMD) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Miri Segal - CEO, MS-IR Moshe Mizrahy - Chief Executive Officer Michael Kreindel - Chief Te...

InMode Reports Third Quarter 2024 Financial Results; Quarterly GAAP Revenue of $130.2 Million (which consists of $98.3 million of net sales in Q3 and $31.9 million of pre-orders from the first half of 2024)
YOKNEAM, Israel, Oct. 30, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results f...

InMode Granted Preliminary Injunction Against Online Sellers Prohibiting Counterfeit Sales of Morpheus8 Radiofrequency Devices and Cartridge Accessories
IRVINE, Calif. , Oct. 24, 2024 /PRNewswire/ -- InMode Ltd.

InMode to Report Third Quarter 2024 Financial Results and Hold Conference Call on October 30, 2024
Expects Q3 Revenue Between $130.0 Million -$130.1 Million (including $31.9 Million in Revenue from First Half of 2024 Pre-orders), Decreases Full Year 2024 Guidance to $410 Million-$420 Million Confer...